A detailed history of Northern Trust Corp transactions in Rallybio Corp stock. As of the latest transaction made, Northern Trust Corp holds 60,942 shares of RLYB stock, worth $61,551. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,942
Previous 228,915 73.38%
Holding current value
$61,551
Previous $306,000 76.8%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.09 - $1.45 $183,090 - $243,560
-167,973 Reduced 73.38%
60,942 $71,000
Q2 2024

Aug 14, 2024

SELL
$1.34 - $2.98 $21,239 - $47,233
-15,850 Reduced 6.48%
228,915 $306,000
Q1 2024

May 14, 2024

SELL
$1.25 - $2.4 $6,278 - $12,055
-5,023 Reduced 2.01%
244,765 $452,000
Q4 2023

Feb 13, 2024

BUY
$1.91 - $4.39 $54,908 - $126,203
28,748 Added 13.01%
249,788 $596,000
Q3 2023

Nov 13, 2023

SELL
$3.37 - $6.16 $6,066 - $11,088
-1,800 Reduced 0.81%
221,040 $744,000
Q2 2023

Aug 11, 2023

BUY
$4.31 - $8.89 $294,825 - $608,120
68,405 Added 44.29%
222,840 $1.26 Million
Q1 2023

May 15, 2023

BUY
$4.37 - $8.75 $86,543 - $173,285
19,804 Added 14.71%
154,435 $881,000
Q4 2022

Feb 13, 2023

BUY
$4.67 - $14.86 $39,699 - $126,324
8,501 Added 6.74%
134,631 $884,000
Q3 2022

Nov 14, 2022

BUY
$7.54 - $14.56 $74,615 - $144,085
9,896 Added 8.51%
126,130 $1.83 Million
Q2 2022

Aug 12, 2022

SELL
$6.26 - $13.65 $95,139 - $207,452
-15,198 Reduced 11.56%
116,234 $878,000
Q1 2022

May 13, 2022

BUY
$6.91 - $15.04 $482,739 - $1.05 Million
69,861 Added 113.46%
131,432 $917,000
Q4 2021

Feb 08, 2022

BUY
$9.3 - $19.91 $37,767 - $80,854
4,061 Added 7.06%
61,571 $588,000
Q3 2021

Nov 15, 2021

BUY
$10.83 - $23.4 $622,833 - $1.35 Million
57,510 New
57,510 $1.01 Million

Others Institutions Holding RLYB

About Rallybio Corp


  • Ticker RLYB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,132,000
  • Market Cap $32.5M
  • Description
  • Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...
More about RLYB
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.